Stocks · News reference
MaxCyte shares are trading higher after the company reported preliminary Q3 core revenue growth of 26% and raised its 2026 revenue guidance.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — MAXCYTE, INC. (MXCT)
Filed: 2026-10-14 AccNo: 0001104659-26-115745 Size: 235 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
MaxCyte Reports Preliminary Q3 Core Revenue Of ~$8.1M, Up 26% YoY; Raises FY26 Revenue Guidance To ~$34M, Core Business Revenue Outlook To ~$28M
MaxCyte, Inc., (NASDAQ: MXCT), a leading cell-engineering company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today